Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ascorbic acid/bicarbonate/glutathione inhalation - Renovion

Drug Profile

Ascorbic acid/bicarbonate/glutathione inhalation - Renovion

Alternative Names: ARINA-1; Bicarbonate/glutathione/ascorbic acid inhalation - Renovion; Glutathione/bicarbonate/ascorbic acid inhalation - Renovion; Inhaled L-glutathione - Renovion

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Renovion
  • Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Antifibrotics; Antineoplastics; Chemoprotectants; Electrolytes; Furans; Oligopeptides; Small molecules; Sugar acids; Vitamins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Lung disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchiolitis obliterans
  • Phase II Bronchiectasis
  • Clinical Phase Unknown Chronic obstructive pulmonary disease
  • No development reported Cystic fibrosis

Most Recent Events

  • 01 Mar 2024 Renovion completes a phase II trial in Bronchiectasis in USA (Inhalation) (NCT05495243)
  • 11 Jan 2024 Renovion completes enrolment in phase-II CLIMB trial in Bronchiectasis in USA (Inhalation) (NCT05495243)
  • 03 Apr 2023 Renovion plans the phase III ALOFT trial in Bronchiolitis obliterans in USA [Inhalation,Liquid] in April 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top